Stockscreener 앱 받기
6.32
0.96%
0.06
시간 외 거래:
6.32
전일 마감가:
$6.26
열려 있는:
$6.25
하루 거래량:
1.11M
Relative Volume:
0.78
시가총액:
$283.13M
수익:
$217.25M
순이익/손실:
$-50.92M
주가수익비율:
-6.32
EPS:
-1
순현금흐름:
$-100.85M
1주 성능:
+5.51%
1개월 성능:
+35.62%
6개월 성능:
-53.77%
1년 성능:
-69.00%
1일 변동 폭
$6.13
$6.585
1주일 범위
$5.83
$6.585
52주 변동 폭
$4.32
$25.42
Prothena Corporation Plc Stock (PRTA) Company Profile
명칭
Prothena Corporation Plc
전화
011-353-1-236-2500
주소
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
PRTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
6.32 | 283.13M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-05-27 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-05-27 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-27 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-01-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-04-24 | 개시 | SVB Securities | Outperform |
| 2023-01-27 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-11-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-06-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-08 | 재확인 | Oppenheimer | Outperform |
| 2021-05-26 | 개시 | Citigroup | Buy |
| 2021-02-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-12-07 | 개시 | H.C. Wainwright | Buy |
| 2020-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-05-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-04-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-04-05 | 재확인 | Barclays | Overweight |
| 2017-11-20 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2017-09-29 | 재확인 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Jefferies | Buy |
| 2017-04-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-04-12 | 개시 | Piper Jaffray | Overweight |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-12-21 | 개시 | SunTrust | Buy |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-08-04 | 재확인 | Barclays | Overweight |
| 2016-05-13 | 개시 | Barclays | Overweight |
| 2016-02-19 | 재확인 | Wedbush | Outperform |
| 2016-01-21 | 개시 | Credit Suisse | Outperform |
모두보기
Prothena Corporation Plc 주식(PRTA)의 최신 뉴스
Prothena announces 63% workforce reduction following birtamimab halt - Investing.com
Prothena (PRTA) Cuts Workforce by 63% to Reduce Costs - GuruFocus
Prothena (PRTA) Shares Rise Following Corporate Restructuring an - GuruFocus
Prothena Announces Major Workforce Reduction to Cut Costs - TipRanks
Prothena (PRTA) Adjusts 2025 Financial Outlook Amid Reorganizati - GuruFocus
Prothena Announces Corporate Restructuring | PRTA Stock News - GuruFocus
Prothena (PRTA) Announces Leadership Changes Amid Workforce Reduction | PRTA Stock News - GuruFocus
Prothena to cut workforce by 63% amid strategic review - Investing.com
Prothena announces corporate restructuring - MarketScreener
Prothena Announces Corporate Restructuring - Business Wire
Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN
Prothena (NASDAQ:PRTA) Shares Pass Below 200 Day Moving Average – Time to Sell? - Defense World
Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA) - Insider Monkey
(PRTA) Trading Signals - news.stocktradersdaily.com
Financial Analysis: Prothena Corporation plc (PRTA)’s Ratios Unveil Key Insights - DWinneX
Prothena stock rises on Parkinson's trial update (PRTA:NASDAQ) - Seeking Alpha
Prothena’s Prasinezumab Advances to Phase III for Parkinson’s - TipRanks
Prothena partner Roche advances Parkinson’s drug to phase 3 By Investing.com - Investing.com Nigeria
Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - BioSpace
Prothena's Partner to Advance Potential Parkinson's Treatment to Phase 3 Development - marketscreener.com
Prothena's Partner Roche to Advance Prasinezumab into Phase III - GuruFocus
Prothena’s SWOT analysis: stock faces challenges after trial setback By Investing.com - Investing.com South Africa
Prothena’s SWOT analysis: stock faces challenges after trial setback - Investing.com
Cantor Fitzgerald Forecasts Prothena FY2026 Earnings - Defense World
Two Sigma Investments LP Buys 27,887 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Prothena Co. plc (NASDAQ:PRTA) Short Interest Update - Defense World
Bank of America Corp DE Purchases 36,944 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
(PRTA) Technical Data - news.stocktradersdaily.com
Millennium Management LLC Has $1.70 Million Holdings in Prothena Co. plc (NASDAQ:PRTA) - Defense World
PROTHENA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Prothena Corporation plc To Contact The Firm - ACCESS Newswire
ProShare Advisors LLC Buys 3,312 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation - MSN
Prothena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Chardan Capital Decreases Earnings Estimates for Prothena - Defense World
Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails - MSN
H.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PT - Insider Monkey
FY2027 EPS Estimates for Prothena Decreased by HC Wainwright - Defense World
Prothena (NASDAQ:PRTA) Given “Underperform” Rating at Bank of America - Defense World
Bank of America Reiterates “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World
Bank of America Reaffirms “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World
Prothena (NASDAQ:PRTA) Receives Underperform Rating from Bank of America - Defense World
The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts - simplywall.st
BofA cuts Prothena stock rating, slashes target to $4 By Investing.com - Investing.com Nigeria
Prothena Corp (PRTA) Sees Downgrade and Price Target Cut by B of A Securities | PRTA Stock News - GuruFocus
Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform - Insider Monkey
BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target - marketscreener.com
Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | P - GuruFocus
Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | PRTA Stock News - GuruFocus
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down - MSN
Prothena (PRTA) Downgraded by BofA Analyst with Lower Price Targ - GuruFocus
Prothena (NASDAQ:PRTA) Price Target Lowered to $81.00 at Piper Sandler - Defense World
Prothena Corporation Plc (PRTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Prothena Corporation Plc 주식 (PRTA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 10% Owner |
May 06 '25 |
Sale |
7.64 |
1,984,053 |
15,164,712 |
5,304,596 |
| EcoR1 Capital, LLC | 10% Owner |
May 05 '25 |
Sale |
8.11 |
977,693 |
7,930,166 |
7,288,649 |
| SCULLY WILLIAM P | 10% Owner |
Jan 14 '25 |
Buy |
12.79 |
100,000 |
1,279,040 |
735,993 |
| SCULLY WILLIAM P | 10% Owner |
Dec 18 '24 |
Buy |
13.93 |
73,436 |
1,022,670 |
1,297,693 |
| SCULLY WILLIAM P | 10% Owner |
Dec 31 '24 |
Buy |
13.01 |
32,000 |
416,393 |
650,193 |
| SCULLY WILLIAM P | 10% Owner |
Dec 20 '24 |
Buy |
15.91 |
2,000 |
31,813 |
618,693 |
1.45%
0.86%
자본화:
|
볼륨(24시간):